The timing of further MRI follow-up after the first performed at 1–3 months should be based on the individual clinical context, including the changes of neuro-ophthalmologic and endocrinological picture, pre-treatment adenoma size, signs of invasiveness, prior surgery, rate of PRL decline and tumor shrinkage on DA treatment, sex, estrogen state, as well as adherence to the medication (97). This evidence concerns the gene PRL and neoplasm.